Announced
Novo Nordisk to acquire Metsera for $9.1bn.
Synopsis
Novo Nordisk, a global healthcare company, offered to acquire Metsera, a clinical-stage biotechnology company, for $9.1bn.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite